LEEDERVILLE-BASED Pharmanet Group Ltd has announced positive results from research into its protein fragment drug, which inhibits reaction to UVB burns. The research shows that the drug, CS-104, suppresses the normal biological response to UVB burning most significantly when applied within five minutes of the injury. The work has been carried out by Pharmanet’s drug discovery subsidiary Cambridge Scientific Pty Ltd, which has been working on acute injury cascade mediators for almost two years. Pharmanet’s drug discovery program was recently expanded to include additional in vitro programs, which are to be undertaken by independent scientists at government-supported medical research facilities in Perth.
© Business News 2017. You may share content using the tools provided but do not copy and redistribute.